

Biocon Biologics France S.A.S
BALANCE SHEET AS AT MARCH 31, 2024

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	<u>Notes</u>	<u>March 31, 2024</u>
ASSETS		
Non-current assets		
Deferred tax asset (net)		88
Total non-current assets		88
Current assets		
Inventories	1	7,406
Financial assets		
(i) Trade receivables	2	16,679
(ii) Cash and cash equivalents	3	1,059
(iii) Other Financial Asset	3(a)	1
Total current assets		25,145
TOTAL		25,233
EQUITY AND LIABILITIES		
Equity		
Equity share capital	4	1
Other equity	5	353
Total equity		354
Current liabilities		
Financial liabilities		
(i) Trade payables	6	23,873
Income-tax liability (net)		205
Provisions	7	201
Other current liabilities	8	600
Total current liabilities		24,879
TOTAL		25,233

Biocon Biologics France S.A.S**STATEMENT OF PROFIT AND LOSS FOR THE PERIOD ENDED MARCH 31, 2024**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	<u>Notes</u>	<u>Period ended</u> <u>March 31, 2024</u>
Income		
Revenue from operations	9	23,382
Total revenue (I)		23,382
Expenses		
Purchases of traded goods	10	18,024
Changes in inventories of traded goods	11	575
Employee benefits expense	12	2,324
Other expenses	13	1,989
Total expenses (II)		22,912
Profit before tax		470
Tax expense		
Current tax		205
Deferred Tax		(88)
Total tax expense		117
Profit for the period		353

Biocon Biologics France S.A.S**STATEMENT OF CASH FLOWS FOR THE PERIOD ENDED MARCH 31, 2024**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	Period ended March 31, 2024
I Cash flows from operating activities	
Profit after tax	353
<u>Adjustments to reconcile profit before tax to net cash flows:</u>	
Tax expense	117
Operating profit before working capital changes	470
Movements in working capital	
(Increase) in trade receivables	(16,680)
(Increase) in trade inventories	(7,406)
Increase in trade payable, other liabilities and provisions	24,674
Cash generated from operations	1,058
Direct taxes paid	-
Net cash flow generated from operating activities	1,058
II Cash flows from investing activities	
Net cash flow from investing activities	-
III Cash flows from financing activities	
Proceeds from issue of equity shares	1
Net cash flow generated from financing activities	1
IV Net increase/(decrease) in cash and cash equivalents (I + II + III)	1,059
V Effect of exchange differences on cash and cash equivalents held in foreign currency	-
VI Cash and cash equivalents at the beginning of the year	-
VIII Cash and cash equivalents at the end of the year (IV + V + VI)	1,059
Reconciliation of cash and cash equivalents as per statement of cash flow	
Cash and cash equivalents	
Balances with banks - on current accounts	1,059
Cash on hand	-
	1,059
Total cash and cash equivalents [Refer note 3]	1,059

Biocon Biologics France S.A.S**Notes to financial statements for the period ended March 31, 2024**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	March 31, 2024
1. Inventories	
Finished Goods	7,406
	<u>7,406</u>
2. Trade receivables	
Other Receivables	
Outstanding for a period less than six months from the date they are due for payment	
Unsecured, considered good	16,679
	<u>16,679</u>
3. Cash and cash equivalents	
Balances with banks:	
On current accounts	1,059
Deposit accounts	-
	<u>1,059</u>
3(a) . Other Financial Assets	
Other Receivables	1
	<u>1</u>
4. Share capital	
Authorised	
Issued, subscribed and fully paid-up	
1,000 Equity shares of EUR 1 each	1
	<u>1</u>
5. Other equity	
Surplus/(deficit) in the statement of profit and loss	
Balance as per the last financial statements	-
Profit / (Loss) for the period	353
Net surplus/(deficit) in the statement of profit and loss	<u>353</u>
Total other equity	353
6. Trade payables	<u>23,873</u>
7. Provisions	
Current	
Compensated absences	201
	<u>201</u>
8. Other liabilities	
(a) Current liabilities	
Statutory liabilities	600
	<u>600</u>

Biocon Biologics France S.A.S**Notes to financial statements for the period ended March 31, 2024**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	Period ended March 31, 2024
9. Revenue from operations	
Sale of Products	
Traded Goods	23,382
	<u>23,382</u>
10. Purchase of traded goods	<u>18,024</u>
	<u>18,024</u>
11. Changes in inventories of traded goods	
Inventory at the beginning of the year	
Traded goods	-
Inventory Transfer during the year	
Traded goods	7,981
Inventory at the end of the year	
Traded goods	7,406
	<u>575</u>
12. Employee benefits expense	
Salaries, wages and bonus	2,306
Staff welfare expenses	18
	<u>2,324</u>
13. Other expenses	
Rent	1
Legal and professional fees	44
Repair and Maintenance	2
Travelling and conveyance	188
Selling expenses	285
Sales promotion expenses	1,369
Printing and stationery	55
Communication expenses	1
Miscellaneous expenses	44
	<u>1,989</u>